8-K: Moleculin Partners for Annamycin Brain Tumor Research

Moleculin Biotech announces a new collaboration with CIC biomaGUNE to conduct investigator-initiated preclinical research on Annamycin for glioblastoma multiforme, a severe form of brain cancer.

Summary

• Moleculin Biotech, Inc. (MBRX) has entered into a research and material transfer agreement with CIC biomaGUNE, a non-profit research organization in Spain.
• The agreement is for investigator-initiated preclinical research evaluating Annamycin for the treatment of glioblastoma multiforme (GBM), a form of brain cancer.
• Moleculin will supply Annamycin, and Jess Ruiz-Cabello, Principal Investigator at CIC biomaGUNE, will conduct the planned preclinical research.
• The studies will evaluate tumor progression following intra-arterial delivery of liposomal Annamycin (L-Annamycin) and Free-Annamycin compared to Doxil and Free-doxorubicin in mouse models.
• Glioblastoma is the most aggressive malignant primary brain tumor, with a median survival of only 15 months and an average annual incidence rate of 3.19 per 100,000 persons in the United States.
• Annamycin currently holds Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML, and Orphan Drug Designation for STS lung metastases.
• Annamycin also has Orphan Drug Designation from the EMA for relapsed or refractory AML.
• Moleculin is also advancing the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (AML).
• The company is developing WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic, and other cancers, and WP1122, an antimetabolite for pathogenic viruses and certain cancer indications.

Sentiment

Score: 7

Explanation: The announcement of a new preclinical collaboration for Annamycin in glioblastoma is a positive development, expanding the drug's potential indications and addressing a high unmet medical need. The involvement of a reputable research institution and the comparative study design are favorable. However, the early preclinical stage of this specific program and the explicit mention of the need for significant additional financing without commitments temper the overall sentiment.

Positives

• Expansion of Annamycin's potential therapeutic applications into glioblastoma multiforme (GBM), an area of profound unmet medical need.
• Collaboration with CIC biomaGUNE, described as a 'premier research team,' enhances the credibility and scientific rigor of the preclinical studies.
• Annamycin has demonstrated clinical activity in acute myeloid leukemia (AML) and soft tissue sarcomas (STS), and preclinical potential in pancreatic, GBM, and certain liver cancers.
• Annamycin holds Fast Track Status and Orphan Drug Designation from the FDA for relapsed/refractory AML and STS lung metastases, and Orphan Drug Designation from the EMA for relapsed/refractory AML.
• The company believes it has 'substantially de-risked' the development pathway for Annamycin in AML following a successful Phase 1B/2 study.

Negatives

• Glioblastoma multiforme (GBM) remains an area of profound unmet medical need, with current therapies offering only limited survival benefit and no meaningful long-term solutions.
• The survival rate for glioblastoma has not changed significantly in the last three decades, highlighting the difficulty in treating this cancer.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, and expectations may prove to be materially different from actual results.
• Moleculin will require significant additional financing to conduct its clinical trials as described, for which the company currently has no commitments.
• The achievement of described milestones assumes the company's ability to secure necessary financing on a timely basis.
• Additional risks are discussed under Item 1A. Risk Factors in the company's most recently filed Form 10-K and subsequent Form 10-Q filings with the SEC.

Future Outlook

Moleculin aims to explore Annamycin's potential to overcome drug delivery and resistance challenges in central nervous system tumors, expanding its therapeutic applications beyond current AML and STS programs. The company is also advancing other pipeline candidates like WP1066 and WP1122, contingent on securing significant additional financing.

Management Comments

• "We are excited to further expand our efforts to advance and develop Annamycin across a number of investigator-initiated studies." Walter Klemp, Chairman and CEO of Moleculin.
• "Annamycin has demonstrated clinical activity in acute myeloid leukemia and soft tissue sarcomas while also showing potential in preclinical models in pancreatic, GBM, and certain liver cancers amongst others." Walter Klemp.
• "GBM remains an area of profound unmet medical need, with current therapies offering only limited survival benefit and no meaningful long-term solutions." Walter Klemp.
• "Collaborating with the premier research team at CIC biomaGUNE provides an important opportunity to explore Annamycins potential to overcome the challenges of drug delivery and resistance in central nervous system tumors." Walter Klemp.
• "This work highlights the potential breadth of Annamycin and underscores our commitment to advancing innovative therapies for patients facing cancers with few or no effective options." Walter Klemp.

Industry Context

The collaboration addresses glioblastoma multiforme (GBM), a highly aggressive brain tumor with a consistently poor prognosis and limited therapeutic advancements over the past three decades. This initiative positions Moleculin within the competitive oncology drug development landscape, specifically targeting an area of significant unmet medical need where existing treatments like Doxil and doxorubicin have shown limited efficacy, particularly in overcoming drug delivery and resistance challenges in CNS tumors.

Comparison to Industry Standards

• The preclinical studies will compare intra-arterial delivery of liposomal Annamycin (L-Annamycin) and Free-Annamycin against Doxil and Free-doxorubicin in mouse models. Doxil (liposomal doxorubicin) is a known anthracycline used in cancer treatment, providing a direct comparative benchmark for Annamycin's efficacy and delivery in GBM models.
• Glioblastoma's median survival of only 15 months highlights the severe limitations of current standard-of-care treatments, indicating a significant gap that Annamycin aims to address.
• The lack of significant change in glioblastoma survival rates over the last three decades underscores the industry's struggle to develop effective therapies for this specific cancer, making any potential breakthrough with Annamycin highly significant.

Stakeholder Impact

• Shareholders: Potential for increased long-term value if Annamycin proves effective in GBM, but also dilution risk due to the explicitly stated need for significant additional financing.
• Patients (GBM): Offers hope for a new, effective treatment option for a highly aggressive cancer with limited current therapies and poor prognosis.
• Research Community: Collaboration with CIC biomaGUNE fosters scientific advancement in oncology, particularly in challenging areas like CNS tumors.

Next Steps

• Conduct investigator-initiated preclinical research evaluating Annamycin for glioblastoma multiforme at CIC biomaGUNE.
• Continue the pivotal Phase 3 MIRACLE Trial (MB-108) for Annamycin in combination with cytarabine for relapsed/refractory AML.
• Potentially make appropriate future filings with the FDA and foreign equivalents regarding the MIRACLE trial.
• Further develop other pipeline candidates, including WP1066 and WP1122.

Key Dates

Recommendation

While the expansion of Annamycin's potential into glioblastoma is a positive strategic move addressing a significant unmet medical need, this is a very early-stage preclinical collaboration. The company explicitly states a need for significant additional financing without current commitments, which introduces a notable financial risk and potential for dilution. The existing Phase 3 trial for AML is more advanced, but the overall financial position and the early nature of this new program suggest a 'hold' recommendation until more clarity on financing and preclinical results emerges.

Keywords

Annamycin, Glioblastoma Multiforme, GBM, Brain Cancer, Preclinical Research, Oncology, Moleculin Biotech, MBRX, CIC biomaGUNE, Drug Development, Anthracycline, Acute Myeloid Leukemia, AML, Soft Tissue Sarcoma, STS